Catabasis Pharmaceuticals (United States)

Recent papers from Catabasis Pharmaceuticals (United States)

1. Comparative Cytotoxicity and Molecular Profiling of Akkermansia muciniphila Postbiotics in AGS and HCT116 CellsJournal of Agriculture and Food Research · 2026
2. Motor Function and Growth Outcomes With Early Corticosteroid Initiation in Duchenne Muscular Dystrophy: An Adjusted Cross‐Trial ComparisonMuscle & Nerve · 2026
3. Assessing the ability of boys with Duchenne muscular dystrophy age 4–7 years to swallow softgel capsules: Clinical trial experience with edasalonexentJournal of Clinical Pharmacy and Therapeutics · 2021
4. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD TrialJournal of Neuromuscular Diseases · 2021
5. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trialNeuromuscular Disorders · 2021
6. Metabolism of bioconjugate therapeutics: why, when, and how?Drug Metabolism Reviews · 2020
7. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne RegistryBMC Neurology · 2019
8. Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid OxidationHepatology · 2018
9. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF- κ B Inhibitor, in Pediatric Patients with Duchenne Muscular DystrophyJournal of Neuromuscular Diseases · 2018
10. “Of Mice and Measures”: A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the ClinicJournal of Neuromuscular Diseases · 2018
11. 2017 White Paper on Recent Issues in Bioanalysis: Aren’t Bmv Guidance/Guidelines ‘ Scientific ’? (Part 1 – LCMS: Small Molecules, Peptides and Small Molecule Biomarkers)Bioanalysis · 2017
12. A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult SubjectsThe Journal of Clinical Pharmacology · 2017
13. Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscleJCI Insight · 2016
14. Fatty Acid Cysteamine Conjugates as Novel and Potent Autophagy Activators That Enhance the Correction of Misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)Journal of Medicinal Chemistry · 2016
15. Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic AcidJournal of Medicinal Chemistry · 2016